Navigation Links
Misonix Exhibits at Annual APTA-CSM Meeting
Date:5/2/2011

FARMINGDALE, N.Y., May 2, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications has announced their attendance at the American Physical Therapy Association's (APTA) Combined Sections Meeting (CSM), which was held in New Orleans, LA, February 10-12, 2011.  Misonix exhibited and presented its SonicOne® Ultrasonic Wound Cleansing and Debridement System to many of the more than 5,000 clinicians in attendance.  In addition, the SonicOne was demonstrated during the Wound Debridement Skills Pre-Conference Course on February 9, 2011.

As part of the educational program a clinical poster was presented on February 12, 2011 that focused on the clinical effectiveness of the SonicOne when used to treat chronic wounds.  Frank Aviles, PT, CWS, WCC, FAACWS, Director of Therapy for a leading long term acute care facility in Natchitoches, LA, was the author and presenter of the material.  Three separate clinical cases were followed from patient admission to wound closure.  In two of the cases, the initial clinical plan included amputation.  However, using a SonicOne debridement protocol to remove non-viable tissue allowed the establishment of a well-granulated wound bed, which contributed to healing, and resulted in both patients retaining their limbs and functional mobility.

The SonicOne is an innovative ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures.  The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is pleased to demonstrate its commitment to the rapidly expanding wound care market by supporting important educational programs like APTA-CSM," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Our wound care product platform, we believe, makes an important contribution to improving patient outcomes and we are pleased when data is presented by clinical experts that support our investment in wound care research and development."

About APTA: APTA, which has a specialty section for advanced wound care, is a national professional organization representing more than 71,000 members.  Its goal is to foster advancements in physical therapy practice, research, and education.  The CSM is a unique conference that focuses on programming designed by all 18 of APTA's specialty sections.

About Misonix:  Misonix, Inc. (NASDAQ: MSON) designs, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually,  Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Announces New Distribution Agreement for Mexico
6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
10. Misonix Announces New Distribution Agreement for Argentina
11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):